Sensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech is discontinuing development of its OTOF-targeted therapy SENS-501, citing a changed competitive environment following the approval of Regeneron’s rival gene therapy.
